Clinical trial
A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung…
NCT00152477 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00152477 |
|---|---|
| Title | A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer |
| Official title | A Two-Part, Open Label Phase II Trial: Part One, Dose Escalation Safety; Part Two, Randomized/Comparing CDP791 Plus Carboplatin/Paclitaxel With Carboplatin/Paclitaxel Alone in Subjects With Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Squamous Non-Small-Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Carboplatin, Paclitaxel, CDP791 10mg/kg, CDP791 20mg/kg |
| Enrollment | 165 |
| Start date | Aug 15, 2005 |
| Primary completion | Jun 25, 2009 |
| Completion | Jun 25, 2009 |
| First posted | Sep 9, 2005 |
| Last update posted | Apr 12, 2022 |
| Countries | Hungary, Poland, Russia |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: